检索结果-南通市图书馆

Role of sodium-glucose co-transporter-2 inhibitors in the management of heart failure in patients with diabetes mellitus

引用

World Journal of Diabetes 2020年第5期11卷 150-154页

作者： Stelina Alkagiet Konstantinos Tziomalos Department of Cardiology Georgios Papanikolaou HospitalThessaloniki 57010Greece First Propedeutic Department of Internal Medicine Medical SchoolAristotle University of ThessalonikiAHEPA HospitalThessaloniki 54636Greece

Heart failure(HF)is a major complication of diabetes mellitus(DM).Patients with DM have considerably higher risk for HF than non-diabetic subjects and HF is also more severe in the *** the rising prevalence of DM,the management of HF in diabetic patients has become the focus of increased *** this context,the findings of several randomized,placebo-controlled trials that evaluated the effects of sodium-glucose co-transporter-2 inhibitors on the risk of hospitalization for HF in patients with type 2 DM represent a paradigm shift in the management of *** agents consistently reduced the risk of hospitalization for HF both in patients with and in those without *** benefits appear to be partly independent from glucose-lowering and have also been reported in patients without ***,there are more limited data regarding the benefit of sodium-glucose co-transporter-2 inhibitors in patients with HF and preserved left ventricular ejection fraction,which is the commonest type of HF in diabetic patients.

关键词： Heart failure Type 2 diabetes mellitus sodium-glucose co-transporter-2 inhibitors Canagliflozin Dapagliflozin Empagliflozin

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor

引用

World Journal of Diabetes 2021年第7期12卷 932-938页

作者： Jelena Marinkovic-Radosevic Maja Cigrovski Berkovic Egon Kruezi Ines Bilic-Curcic Anna Mrzljak Department of Endocrinology Diabetes and MetabolismSisters of Charity Clinical Hospital CentreZagreb 10000Croatia Department of Endocrinology DiabetesMetabolism and Clinical PharmacologyClinical Hospital DubravaZagreb 10000Croatia Department of Kinesiological Anthropology and Methodology Faculty of KinesiologyUniversity of ZagrebZagreb 10000Croatia Department of Gynecology and Obstetrics Sisters of Charity Clinical Hospital CentreZagreb 10000Croatia Department of Pharmacology Faculty of MedicineUniversity of J.J.Strossmayer OsijekOsijek 31000Croatia Clinical Hospital Center Osijek Osijek 31000Croatia School of Medicine University of ZagrebZagreb 10000Croatia Department of Gastroenterology and Hepatology University Hospital Centre ZagrebZagreb 10000Croatia

Polycystic ovary syndrome(PcoS)is the most common endocrinopathy in women of reproductive age associated with long-term metabolic and cardiovascular consequences.A plethora of symptoms and their severity differentiate on an individual level,giving the syndrome numerous *** to menstrual cycle abnormalities,women suffer from irregular menstrual bleeding,difficulty in conception,and ***,the risk of pregnancy complications such as gestational diabetes mellitus,hypertensive disorders of pregnancy,and preterm birth are higher in women with PcoS than in the general ***,women with PcoS have comorbidities such as dyslipidemia,obesity,glucose intolerance or diabetes type 2,non-alcoholic fatty liver disease,and metabolic syndrome,which all influence the treatment *** insulinsensitizing agents,although good for some of the metabolic derangements,do not offer long-term cardiovascular benefits;therefore,new treatment options are of paramount ***-glucose co-transporter-2(SGLT-2)inhibitors,a new class of antidiabetic agents with beneficial cardiovascular,bodyweight,and antihyperglycemic effects,although not approved for the treatment of PcoS,might be an attractive therapeutic addition in the PcoS ***,recent studies with SGLT-2 inhibitors showed promising improvements in anthropometric parameters and body composition in patients with *** is important to further explore the SGLT-2 inhibitors potential as an early therapeutic option because of the PcoS-related risk of metabolic,reproductive,and psychological consequences.

关键词： Polycystic ovary syndrome sodium-glucose co-transporter-2 inhibitors Metabolic risk Cardiovascular risk Metabolic syndrome Insulin resistance Obesity Type 2 diabetes mellitus Dyslipidemia

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：